In this study, the effects of these inhibitors on the expression levels of PD-1, PD-L1, and drug resistance-related proteins, including ABCG2, MDR-1, and MRP-1, were evaluated across breast cancer cell lines within distinct immune microenvironment contexts. The gene discussed is ABCG2; the disease is breast carcinoma.